Fundacion Instituto Valenciano De Oncologia

The Fundacion Instituto Valenciano De Oncologia in Valencia is running a broad portfolio in oncology, with many studies focused on neoplasms and advanced solid tumors. Research here often aims to test new cancer therapies, improve treatment effectiveness, and expand options for patients with difficult-to-treat disease.

• Studies in advanced and metastatic cancers across multiple tumor types
• Evaluation of new immunotherapy, targeted therapy, and combination approaches
• Research on treatment effectiveness and disease control in resistant or recurrent disease

This site’s cancer research spans many tumor types, including breast, lung, colorectal, ovarian, and urothelial cancers, reflecting a strong focus on developing better treatments for both common and complex malignancies.

A major part of the trial activity centers on breast cancer, especially HER2-positive, hormone receptor-positive, and triple-negative breast cancer. These studies explore ways to improve early treatment, reduce recurrence, and help patients with advanced or metastatic disease.

• Early-stage and locally advanced breast cancer
• Metastatic and recurrent breast cancer with biomarker-driven subgroups
• Testing targeted therapies, endocrine-based strategies, and immunotherapy combinations

Research at the site also includes efforts to refine treatment selection for patients with PIK3CA mutations, BRCA-related disease, and other molecular features that may influence therapy response.

The site has extensive research in prostate cancer, bladder cancer, urothelial carcinoma, and renal cell carcinoma. Many of these trials are designed to improve outcomes in advanced disease, prevent recurrence, or compare new approaches with standard treatment.

• Metastatic and castration-resistant prostate cancer
• Muscle-invasive and non-muscle invasive bladder cancer
• Advanced renal cell carcinoma and urothelial cancer

Several studies at Fundacion Instituto Valenciano De Oncologia focus on combining modern systemic therapies with surgery or radiation, while others look at better ways to manage high-risk or treatment-resistant disease.

Another prominent area is respiratory tract diseases, especially non-small cell lung cancer, small-cell lung cancer, and head and neck squamous cell carcinoma. The trials in this field aim to improve survival, reduce progression, and identify more effective treatment combinations.

• Locally advanced, metastatic, and resectable lung cancer
• Head and neck squamous cell carcinoma in recurrent or advanced settings
• Testing immunotherapy, targeted therapy, and perioperative treatment strategies

This research reflects a strong interest in both first-line treatment and strategies for patients whose cancer has returned or spread.

Clinical trials in female urogenital diseases and related cancer care include ovarian cancer, endometrial cancer, and cervical cancer. These studies are focused on improving treatment for advanced, recurrent, or resistant disease.

• Platinum-resistant ovarian and fallopian tube cancers
• Advanced or recurrent endometrial cancer
• Locally advanced and recurrent cervical cancer

The research often evaluates new targeted and immune-based therapies, with the goal of extending disease control and offering more personalized treatment options.

The site also conducts studies in skin and connective tissue diseases, with a strong emphasis on melanoma, cutaneous squamous cell carcinoma, and actinic keratosis. These trials aim to improve prevention, reduce recurrence, and test newer treatments for advanced skin cancers.

• Advanced and resected melanoma
• High-risk cutaneous squamous cell carcinoma
• Actinic keratosis and other precancerous skin conditions

Overall, this area combines studies of treatment effectiveness with efforts to lower the risk of progression in patients with high-risk skin lesions or invasive cancer.

A significant part of the research program is centered on precision oncology, using tumor markers such as HER2, EGFR, KRAS, PIK3CA, and BRCA to guide treatment development. These studies aim to match therapies more closely to the biology of each cancer.

• Biomarker-selected breast, lung, ovarian, and colorectal cancers
• Molecularly defined solid tumors and advanced malignancies
• Testing targeted agents and immunotherapy in selected patient groups

This approach supports more individualized cancer care and helps identify which patients are most likely to benefit from specific treatments.

Beyond direct cancer treatment, the site includes studies that look at treatment optimization, patient experience, and supportive care in oncology. These trials may assess recurrence prevention, symptom management, or ways to make treatment delivery more practical for patients and clinicians.

• Studies focused on recurrence prevention and long-term disease control
• Research on treatment tolerability and patient-centered outcomes
• Evaluations of care strategies that may improve convenience and efficiency

At Fundacion Instituto Valenciano De Oncologia, this broader research helps complement the main cancer-focused trials and supports better overall care for patients.